Clinical data supporting the expanded approval come from the Phase I/II open-label multi-centre BUR-CL207 trial.
Tract Bio ("Tract"), a biotechnology company discovering and developing novel therapies for cancer and inflammatory disease, today announced presentations at the American Association for Cancer ...
Millions of people with knee osteoarthritis live with daily pain and stiffness that erode their ability to walk, climb stairs ...
PDRN—short for polydeoxyribonucleotide (say that five times fast)—is one of the buzziest ingredients of the year. Studies ...